• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 75
  • 62
  • 8
  • 5
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • Tagged with
  • 173
  • 72
  • 32
  • 25
  • 23
  • 15
  • 13
  • 13
  • 13
  • 12
  • 12
  • 12
  • 12
  • 11
  • 11
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
21

Eficácia da associação de tadalafila e fluoxetina de liberação lenta no tratamento da ejaculação precoce / Efficacy of tadalafil associated with once-weekly fluoxetine in premature ejaculation

Mattos, Rogério de Moraes 12 August 2005 (has links)
Introdução e objetivos: A ejaculação precoce é uma forma de disfunção sexual presente em 25,8% dos homens brasileiros. O objetivo do presente estudo é avaliar se a associação de tadalafila, um inibidor da fosfodiesterase-5 e fluoxetina, um inibidor da recaptação da serotonina em uma apresentação de liberação lenta, ambos tomados uma vez por semana, pode prolongar o tempo de latência da ejaculação em homens com ejaculação precoce. Pacientes e Métodos: Sessenta pacientes com ejaculação precoce e sem disfunção erétil foram avaliados. A idade média foi 45,5 anos de idade (desvio padrão +/- 9,6). O tempo médio de ejaculação antes do início do tratamento era 51,3 segundos (desvio padrão +/- 23 segundos) e não foi estatisticamente significativo entre os grupos (p=0,805). Foram distribuídos de forma aleatória e duplo-cega em 4 grupos, conforme a medicação recebida: (1) fluoxetina 90 mg e placebo, (2) tadalafila 20 mg e fluoxetina 90 mg, (3) tadalafila 20 mg e placebo, e (4) placebo com placebo. Antes de iniciar qualquer medicamento, os pacientes anotaram o tempo de latência para ejaculação com um mesmo cronômetro uma vez por semana, durante 3 semanas. À partir do início do uso dos medicamentos, os pacientes cronometraram o tempo em nove ocasiões, uma vez por semana. Foi usado fluoxetina 90 mg ou placebo semanalmente e tadalafila 20 mg ou placebo em um intervalo de até 36 horas da presumida relação sexual com parceira heterossexual regular. Os pacientes foram prospectivamente seguidos a cada 3 semanas durante 12 semanas. Resultados: A comparação dos grupos com análise de variância (ANOVA) unidirecional demonstrou diferença estatisticamente significativa no tempo de ejaculação após tratamento (p<0,001). O maior aumento em relação ao tempo basal foi observado no grupo que associou tadalafila 20 mg com fluoxetina 90 mg semanalmente (p<0,001). Reações adversas foram observadas, tendo sido toleradas e equivalentes entre os grupos usando princípio ativo. Conclusão: Tadalafila 20 mg utilizada em um período de 36 horas de atividade sexual associado com fluoxetina 90 mg de liberação lenta usada semanalmente, significativamente aumentou o tempo de latência de ejaculação em homens com ejaculação precoce, quando comparados com cada droga usada isoladamente, beneficiando esses pacientes sem a necessidade do uso diário de medicamentos. / Introduction and Objectives: Premature ejaculation is a sexual disorder present in 25.8% of brazilian men. The aim of the present study is to evaluate if the association of tadalafil, a phosphodiesterase-5 inhibitor and fluoxetine, a selective serotonin reuptake inhibitor in a slow release presentation, both taken once a week, can prolong the intravaginal ejaculatory latency time (IELT) in men with premature ejaculation. Methods: Sixty patients with premature ejaculation and no erectile dysfunction were enrolled in the protocol. Mean age was 45.5 years (range 24 - 64 years, standard deviation +/- 9.6). They were randomly assigned in a double-blind manner into 4 groups to use the medications: (1) fluoxetine 90 mg and placebo, (2) tadalafil 20 mg and fluoxetine 90 mg, (3) tadalafil 20 mg and placebo, and (4) two different placebo capsules. Before starting any medication, each individual timed the IELT with a given stopwatch in 3 different days, and likewise weekly during the treatment period. Mean IELT before starting treatment was 51.3 seconds (sd: +/- 23 seconds), and was not different between groups (p=0.805). They took fluoxetine 90 mg or placebo once a week, and tadalafil 20 mg or placebo in a 36-hour frame of intended sexual intercourse with a regular heterosexual partner. Patients were prospectively followed every 3 weeks during a 12-week interval. Results: Comparison between groups with oneway ANOVA demonstrated a statistically significant difference in post-treatment IELT (p<0.001). The greatest increase in time from baseline IELT was observed in patients in the tadalafil plus fluoxetine group (p<0.001). Side effects were observed and tolerated, being equivalent in groups using active drugs. Conclusion: Tadalafil 20 mg taken in a 36-hour window for sexual intercourse associated with fluoxetine 90 mg in a slow release form taken weekly, significantly increased the intravaginal ejaculatory latency time from baseline in men with premature ejaculation, when compared to either drug taken solely, benefiting patients without the need to be medicated on a daily basis.
22

Residual symptoms in pediatric depression after acute pharmacological treatment

Sowell, Morgan Michelle. January 2006 (has links)
Thesis (M.S.) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Vita. Bibliography: pp.40-43.
23

Medication adherence in children and adolescents with major depressive disorder

Sternweis, Kathryn VanArsdale January 2006 (has links)
Thesis (M.S.) -- University of Texas Southwestern Medical Center at Dallas, 2006. / Vita. Bibliography: pp. 159-175.
24

Como viver sem meu Prozac ? Uma análise antropológica dos discursos sobre o consumo de fluoxetina em um site de relacionamento / How to live without my Prozac ? An anthropological analysis of the discourses on the use of fluoxetine in a trusted relationship

Cecília Maria Silveira Chaves 31 May 2007 (has links)
Neste trabalho enfocaremos o consumo de antidepressivos, buscando questionar a posição mais comumente aceita para explicar o alto consumo dessas substâncias, que geralmente responsabiliza os ardilosos estratagemas das indústrias farmacêuticas ou a hegemonia da psiquiatria biológica na medicina. Acreditamos que as respostas devem ser buscadas em análises mais profundas, e não simplesmente na demonização desse ou daquele ator social considerado isolada,e,tem, pois admitimos que no consumo se constrói parte da racionalidade integrativa e comunicativa de uma sociedade, logo, pensar o consumo implica em um enfoque dos sujeitos enquanto consumidores, indivíduos e cidadãos. Partindo desses considerações, analisaremos o consumo de antidepressivos pela ótica dos usuários através da análise do conteúdo de um site de relacionamentos muito popular na internet brasileira, conhecido como Orkut. / In this work we will focus on the use of antidepressants, seeking to question the position most commonly accepted to explain the high consumption of these substances, which usually blames "cunning ploys" of the pharmaceutical industry or the hegemony of biological psychiatry in medicine. We believe that the answers are to be found in deeper analysis, and not simply on the demonization of this or that social actor considered isolated, and has since admitted that "in the consumption builds part of integrative and communicative rationality of a society" thus think consumption implies a focus subjects as consumers, individuals and citizens. Based on these considerations, we analyze the consumption of antidepressants by the viewpoint of the user by analyzing the content of a site very popular relationships in the Brazilian Internet, known as Orkut.
25

Como viver sem meu Prozac ? Uma análise antropológica dos discursos sobre o consumo de fluoxetina em um site de relacionamento / How to live without my Prozac ? An anthropological analysis of the discourses on the use of fluoxetine in a trusted relationship

Cecília Maria Silveira Chaves 31 May 2007 (has links)
Neste trabalho enfocaremos o consumo de antidepressivos, buscando questionar a posição mais comumente aceita para explicar o alto consumo dessas substâncias, que geralmente responsabiliza os ardilosos estratagemas das indústrias farmacêuticas ou a hegemonia da psiquiatria biológica na medicina. Acreditamos que as respostas devem ser buscadas em análises mais profundas, e não simplesmente na demonização desse ou daquele ator social considerado isolada,e,tem, pois admitimos que no consumo se constrói parte da racionalidade integrativa e comunicativa de uma sociedade, logo, pensar o consumo implica em um enfoque dos sujeitos enquanto consumidores, indivíduos e cidadãos. Partindo desses considerações, analisaremos o consumo de antidepressivos pela ótica dos usuários através da análise do conteúdo de um site de relacionamentos muito popular na internet brasileira, conhecido como Orkut. / In this work we will focus on the use of antidepressants, seeking to question the position most commonly accepted to explain the high consumption of these substances, which usually blames "cunning ploys" of the pharmaceutical industry or the hegemony of biological psychiatry in medicine. We believe that the answers are to be found in deeper analysis, and not simply on the demonization of this or that social actor considered isolated, and has since admitted that "in the consumption builds part of integrative and communicative rationality of a society" thus think consumption implies a focus subjects as consumers, individuals and citizens. Based on these considerations, we analyze the consumption of antidepressants by the viewpoint of the user by analyzing the content of a site very popular relationships in the Brazilian Internet, known as Orkut.
26

Estudo da biodegradação do hidrocloridrato de fluoxetina, empregando ensaios de respirometria e toxicidade / Biodegradation of the fluoxetine hidrocloride using respirometric and toxicological methods

Caminada, Suzete Maria Lenzi 12 December 2008 (has links)
Orientador: Alexandre Nunes Ponezi / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Engenharia Civil, Arquitetura e Urbanismo / Made available in DSpace on 2018-08-13T11:10:42Z (GMT). No. of bitstreams: 1 Caminada_SuzeteMariaLenzi_M.pdf: 5250587 bytes, checksum: 52265efd2c8ae0079d610af85e15b3b3 (MD5) Previous issue date: 2008 / Resumo: A Comissão da União Européia e o comitê científico de toxicologia, ecotoxicologia e ambiente, identificaram, a necessidade da obtenção de dados sobre os efeitos dos fármacos no ambiente. Estes compostos e seus metabólitos são introduzidos no ambiente, pelo esgoto em quantidades que superam 100 toneladas/ano. A literatura científica comenta que a presença de fármacos no ambiente é, geralmente, pequena quando comparada a outros produtos químicos. No entanto, a alta persistência de vários destes compostos e sua contínua reposição aumentam o risco de exposição crônica para os organismos aquáticos, como também para os humanos. Um destes compostos, Hidrocloridrato de Fluoxetina, medicamento bastante utilizado no tratamento da ansiedade e distúrbios de comportamento, obesidade e bulemia nervosa, tem sido reportado como um causador de distúrbios em organismos aquáticos. Os resultados demonstram que o fármaco em estudo foi parcialmente degradado pelos organismos no sistema teste com uma remoção de 27%. Os ensaios ecotoxicológicos indicaram que os fármacos apresentam toxicidades diferentes entre as formulações estudadas. As avaliações da toxicidade das amostras geradas pelo sistema de respirometria apresentaram uma redução na toxicidade. Os ensaios indicam uma possível acumulação ambiental com conseqüências prejudiciais aos organismos aquáticos. / Abstract: The Commission of the European Union and the scientific committee of toxicology, ecotoxicology and environment 1990, identified, the need of the obtaining of data on the effects of the drugs in the environment. These composed and they metabolics are, introduced in the environment, through the wastewater sanitary, in larger proportions than 100 ton/year. The scientific literature comments that the drugs presences in the environment are generally, small when compared the other chemical products. However the high persistence of several of these composed and its continuous replacement increases the risk of chronic exhibition for the aquatic organisms as well as for the humans. One of these substance, Hidrocloridrate of Fluoxetine, medication quite used in the treatment of the anxiety and disturbances of behavior, obesity and nervous bulemy, it has been reported as a caused of disturbances in aquatic organisms. The results demonstrate that the drug in study was degraded partially by the organisms in test system with a maximum removal of approximately 27%. The toxicological rehearsals indicated that the drugs presents show different toxicicity among the studied formulations. The evaluation of the toxicicity of the samples generated by the system presented a reduction in the toxicicity. The rehearsals indicate a possible environmental accumulation with harmful consequences to the aquatic organisms. / Mestrado / Saneamento e Ambiente / Mestre em Engenharia Civil
27

Eficácia da associação de tadalafila e fluoxetina de liberação lenta no tratamento da ejaculação precoce / Efficacy of tadalafil associated with once-weekly fluoxetine in premature ejaculation

Rogério de Moraes Mattos 12 August 2005 (has links)
Introdução e objetivos: A ejaculação precoce é uma forma de disfunção sexual presente em 25,8% dos homens brasileiros. O objetivo do presente estudo é avaliar se a associação de tadalafila, um inibidor da fosfodiesterase-5 e fluoxetina, um inibidor da recaptação da serotonina em uma apresentação de liberação lenta, ambos tomados uma vez por semana, pode prolongar o tempo de latência da ejaculação em homens com ejaculação precoce. Pacientes e Métodos: Sessenta pacientes com ejaculação precoce e sem disfunção erétil foram avaliados. A idade média foi 45,5 anos de idade (desvio padrão +/- 9,6). O tempo médio de ejaculação antes do início do tratamento era 51,3 segundos (desvio padrão +/- 23 segundos) e não foi estatisticamente significativo entre os grupos (p=0,805). Foram distribuídos de forma aleatória e duplo-cega em 4 grupos, conforme a medicação recebida: (1) fluoxetina 90 mg e placebo, (2) tadalafila 20 mg e fluoxetina 90 mg, (3) tadalafila 20 mg e placebo, e (4) placebo com placebo. Antes de iniciar qualquer medicamento, os pacientes anotaram o tempo de latência para ejaculação com um mesmo cronômetro uma vez por semana, durante 3 semanas. À partir do início do uso dos medicamentos, os pacientes cronometraram o tempo em nove ocasiões, uma vez por semana. Foi usado fluoxetina 90 mg ou placebo semanalmente e tadalafila 20 mg ou placebo em um intervalo de até 36 horas da presumida relação sexual com parceira heterossexual regular. Os pacientes foram prospectivamente seguidos a cada 3 semanas durante 12 semanas. Resultados: A comparação dos grupos com análise de variância (ANOVA) unidirecional demonstrou diferença estatisticamente significativa no tempo de ejaculação após tratamento (p<0,001). O maior aumento em relação ao tempo basal foi observado no grupo que associou tadalafila 20 mg com fluoxetina 90 mg semanalmente (p<0,001). Reações adversas foram observadas, tendo sido toleradas e equivalentes entre os grupos usando princípio ativo. Conclusão: Tadalafila 20 mg utilizada em um período de 36 horas de atividade sexual associado com fluoxetina 90 mg de liberação lenta usada semanalmente, significativamente aumentou o tempo de latência de ejaculação em homens com ejaculação precoce, quando comparados com cada droga usada isoladamente, beneficiando esses pacientes sem a necessidade do uso diário de medicamentos. / Introduction and Objectives: Premature ejaculation is a sexual disorder present in 25.8% of brazilian men. The aim of the present study is to evaluate if the association of tadalafil, a phosphodiesterase-5 inhibitor and fluoxetine, a selective serotonin reuptake inhibitor in a slow release presentation, both taken once a week, can prolong the intravaginal ejaculatory latency time (IELT) in men with premature ejaculation. Methods: Sixty patients with premature ejaculation and no erectile dysfunction were enrolled in the protocol. Mean age was 45.5 years (range 24 - 64 years, standard deviation +/- 9.6). They were randomly assigned in a double-blind manner into 4 groups to use the medications: (1) fluoxetine 90 mg and placebo, (2) tadalafil 20 mg and fluoxetine 90 mg, (3) tadalafil 20 mg and placebo, and (4) two different placebo capsules. Before starting any medication, each individual timed the IELT with a given stopwatch in 3 different days, and likewise weekly during the treatment period. Mean IELT before starting treatment was 51.3 seconds (sd: +/- 23 seconds), and was not different between groups (p=0.805). They took fluoxetine 90 mg or placebo once a week, and tadalafil 20 mg or placebo in a 36-hour frame of intended sexual intercourse with a regular heterosexual partner. Patients were prospectively followed every 3 weeks during a 12-week interval. Results: Comparison between groups with oneway ANOVA demonstrated a statistically significant difference in post-treatment IELT (p<0.001). The greatest increase in time from baseline IELT was observed in patients in the tadalafil plus fluoxetine group (p<0.001). Side effects were observed and tolerated, being equivalent in groups using active drugs. Conclusion: Tadalafil 20 mg taken in a 36-hour window for sexual intercourse associated with fluoxetine 90 mg in a slow release form taken weekly, significantly increased the intravaginal ejaculatory latency time from baseline in men with premature ejaculation, when compared to either drug taken solely, benefiting patients without the need to be medicated on a daily basis.
28

The Effect of Fluoxetine on Ovulation in Rabbits

Barry, Amanda 04 November 2019 (has links)
No description available.
29

Eszopiclone Facilitation of the Antidepressant Efficacy of Fluoxetine Using a Social Defeat Stress Model in the Mouse

Noel, Daniel M., Hughes, Benjamin A., Sheppard, Brianna, Thompson, Kimberly N., Ordway, Gregory A., Brown, Russell W. 16 November 2008 (has links)
This study was designed to analyze whether the sleep aid eszopiclone may facilitate the efficacy of fluoxetine on social defeat stress (SDS) in the mouse. Subjects were adult male ‘intruder’ C57/B6 mice that that were exposed to a retired ‘resident’ male breeder ICR mouse in this animal’s home cage for a 5 min period for 10 consecutive days. During this interaction, the resident would establish physical dominance of the intruder. After confrontation, the intruder was housed in a cage that allowed sensory contact with the resident mouse but that would not allow physical interaction during the 10-day period. Once the 10 days of interaction were complete, all animals were assigned to one of four drug treatment groups, and treatment was given for up to 18 days: saline treatment, fluoxetine (10 mg/kg) only, eszopiclone only (3 mg/kg), or fluoxetine + eszopiclone. A social interaction test was given on days 1, 5, 10, and 15 of drug treatment. Sucrose preference was also tested during the interaction test. Results showed that eszopiclone facilitated the action of fluoxetine on the interaction test at days 1 and 5, and these two groups were equivalent on days 10 and 15. SDS produced a significant decrease in sucrose preference that was not affected by drug treatment. This study demonstrates that eszopiclone facilitates the action of fluoxetine in the SDS paradigm, paralleling clinical studies that showed facilatory effects of the drug combination in depressed patients. Future work will examine neurochemical mechanisms underlying the effects of this drug combination
30

pH Effects on the Sorption of Fluoxetine and Sulfamethoxazole by Three Powdered Activated Carbons

Schneider, James D. 01 May 2018 (has links)
Pharmaceuticals and personal care products (PPCPs) are widely used throughout the world. PPCPs are emerging as pollutants of concern and may pose a risk in the future to drinking water supplies. Two such compounds are sulfamethoxazole (SMXL) and fluoxetine (FLX). These ionizable compounds are not readily removed from water by conventional water treatment technologies. Powdered activated carbon (PAC) is a useful material for removing contaminants from water and is currently used in many water treatment applications. PACs may carry either a net positive or negative surface charge depending on the pH of solution. This study examined the hypothesis that the electrostatic interactions between three PACs’ surface charges and the charges of sulfamethoxazole’s and fluoxetine’s ionizable functional groups would lead to greater sorption efficiency than non-electrostatic interactions alone. Samples containing SMXL or FLX, were treated with varying doses of PAC, and mixed for three hours. The pH of samples were adjusted between experiments to determine if interaction between the polar contaminants and charged surface of PAC significantly impacted removal of the contaminant from solution. Analysis of the treated samples showed the effects of pH and varying PACs on the removal of SMXL and FLX from solution. It was observed that pH of the solution did play a significant role in the removal of contaminant in a number of the experiments, but that under other conditions where greater removal was anticipated based on predicted electrostatic interactions, it did not. These conditions included pH conditions where the contaminant existed predominantly in a negatively charged form. While not the initial focus of this study, it was observed that pore size distribution of the PACs may play a more significant role in the removal of ionizable compounds, especially in the case of fluoxetine, than electrostatic interactions.

Page generated in 0.0379 seconds